News
1d
News-Medical.Net on MSNNew therapeutic approach targets PCSK9 to regulate blood cholesterol levelsWhen the amount of cholesterol in the blood is too high, hypercholesterolemia can develop, causing serious damage to the ...
2d
Medpage Today on MSNPrivate Equity in Heart Failure Care; Oral PCSK9 Inhibitor Wins; First Robotic TAVRThe world's first robotic transcatheter aortic valve replacement (TAVR) explant and aortic valve replacement took place at ...
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
A new method, based on the use of molecules known as polypurine hairpins, facilitates the uptake of cholesterol by cells and ...
Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...
Currently available PCSK9-targeting therapies are Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab), ...
Explore more
Topline data were announced from two phase 3 trials evaluating enlicitide decanoate for the treatment of adults with hyperlipidemia.
Results from the Phase III CORALreef HeFH and CORALreef AddOn studies demonstrated tatistically significant and clinically ...
3d
ZME Science on MSNRevolutionary single-dose cholesterol treatment could reduce levels by up to 69%The patients came in with high cholesterol. And it was the kind that clings stubbornly to arteries and shadows families for ...
Merck said early Monday that a new cholesterol-lowering pill worked well in two late-stage trials, boosting the stock in ...
9d
News-Medical.Net on MSNPCSK9 protein controls how pancreatic cancer cells spread to the lung or liverA protein called PCSK9 determines how pancreatic cancer cells metastasize to different parts of the body.
Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results